

Sascha A Tuchman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8190739/publications.pdf>

Version: 2024-02-01

40
papers

769
citations

623734

14
h-index

526287

27
g-index

45
all docs

45
docs citations

45
times ranked

1156
citing authors

#	ARTICLE	IF	CITATIONS
1	Geriatric-assessment-identified functional deficits among adults with multiple myeloma with normal performance status. <i>Journal of Geriatric Oncology</i> , 2022, 13, 182-189.	1.0	13
2	What Is Multiple Myeloma?. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 497.	7.4	16
3	Physical Function, Psychosocial Status, and Symptom Burden Among Adults with Plasma Cell Disorders and Associations with Quality of Life. <i>Oncologist</i> , 2022, 27, 694-702.	3.7	5
4	Prevalence and clinical correlates of cognitive impairment in adults with plasma cell disorders. <i>Journal of Geriatric Oncology</i> , 2022, , .	1.0	1
5	Phase 1 open-label study of panobinostat, lenalidomide, bortezomib+â€‰dexamethasone in relapsed and relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 20.	6.2	11
6	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021, 35, 3526-3533.	7.2	13
7	A phase I<sc>II</sc> study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance <sc>A061202</sc>). <i>American Journal of Hematology</i> , 2021, 96, 1595-1603.	4.1	15
8	A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 149.	6.2	5
9	A Cross-Sectional Analysis of County-Level Social Vulnerability and Physical Frailty Among Adults with Hematological Malignancies. <i>Blood</i> , 2021, 138, 4130-4130.	1.4	2
10	Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (Î±CD38 mAb). <i>Blood</i> , 2021, 138, 1651-1651.	1.4	2
11	Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment. <i>Blood</i> , 2021, 138, 2751-2751.	1.4	3
12	Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 2748-2748.	1.4	8
13	A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41). <i>Blood</i> , 2021, 138, 4776-4776.	1.4	1
14	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, 192.	6.2	62
15	The Spectrum of Monoclonal Immunoglobulin-Associated Diseases. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 997-1008.	2.2	0
16	Thrombosis in the modern era of multiple myeloma. <i>Blood</i> , 2020, 136, 1019-1021.	1.4	3
17	Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma. <i>JCO Oncology Practice</i> , 2020, 16, e751-e757.	2.9	2
18	Simplified frailty assessment tools: are we really capturing frailty or something else?. <i>Leukemia</i> , 2020, 34, 1967-1969.	7.2	11

#	ARTICLE	IF	CITATIONS
19	Multiple Myeloma in Older Adults. , 2020, , 549-565.		0
20	A comparison of response in the presence or absence of a delay in induction therapy with bortezomib, lenalidomide, and dexamethasone. Journal of Oncology Pharmacy Practice, 2019, 25, 1692-1698.	0.9	2
21	Geriatric Assessment in Older Adults with Multiple Myeloma. Journal of the American Geriatrics Society, 2019, 67, 987-991.	2.6	42
22	Reference intervals and diagnostic ranges for serum free λ and free κ immunoglobulin light chains vary by instrument platform: Implications for classification of patient results in a multi-center study. Clinical Biochemistry, 2018, 58, 100-107.	1.9	25
23	Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. Hematological Oncology, 2017, 35, 752-759.	1.7	5
24	Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (â€œVCD-Liteâ€) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. Journal of Geriatric Oncology, 2017, 8, 165-169.	1.0	11
25	Non-secretory multiple myeloma: from biology to clinical management. OncoTargets and Therapy, 2016, Volume 9, 7583-7590.	2.0	39
26	Re: intrathecal vincristine as mentioned in â€œoverview of recent trends in diagnosis and management of leptomeningeal multiple myelomaâ€™ by Yellu <i>et al</i>.. Hematological Oncology, 2016, 34, 224-224.	1.7	0
27	Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults. Clinics in Geriatric Medicine, 2016, 32, 191-205.	2.6	4
28	Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. Journal of Clinical Apheresis, 2015, 30, 176-182.	1.3	40
29	Multiple Myeloma in the Older Adult: Better Prospects, More Challenges. Journal of Clinical Oncology, 2014, 32, 2531-2540.	1.6	61
30	Clinician Approaches to Myeloma in Academia and the Community : An in-Practice Qualitative Study. Blood, 2014, 124, 6010-6010.	1.4	0
31	Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Advances in Hematology, 2012, 2012, 1-8.	1.0	5
32	High-Risk Multiple Myeloma: Does it Still Exist?. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S70-S76.	0.4	3
33	Characterizing the developmental pathways <i>TTF-1</i> , <i>NKX2-8</i> , and <i>PAX9</i> in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5312-5317.	7.1	50
34	Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma. Clinical Cancer Research, 2009, 15, 7553-7561.	7.0	18
35	Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, 4197-4203.	1.6	69
36	Age-Specific Differences in Oncogenic Pathway Dysregulation in Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2009, 27, 5580-5586.	1.6	90

#	ARTICLE	IF	CITATIONS
37	Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer. JAMA - Journal of the American Medical Association, 2008, 299, 1574.	7.4	89
38	Gene Expression Profiles with Signatures of Tumor Biology and Chemotherapy Sensitivity May Provide a Novel Approach to Maximize Response to Induction Therapy in Patients with Acute Myeloid Leukemia.. Blood, 2008, 112, 2252-2252.	1.4	0
39	HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC). Journal of Carcinogenesis, 2005, 4, 8.	2.5	8
40	Comparison of Retroviral Transduction Efficiency in CD34+Cells Derived from Bone Marrow versus G-CSF-Mobilized or G-CSF Plus Stem Cell Factor-Mobilized Peripheral Blood in Nonhuman Primates. Stem Cells, 2004, 22, 1062-1069.	3.2	18